Hoang Anh T. Phan

Hoang Anh T. Phan

Auto-generated profile, based on publicly available information

Hoang Anh T. Phan

Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, 231 South 34th Street, Philadelphia, PA, 19104, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2024 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
HDHaotian Du
Haotian Du
LMLeena Mallik
Leena Mallik
DHDaniel Hwang
Daniel Hwang
YSYi Sun
Yi Sun
CKChengzi Kaku
Chengzi Kaku
PHPo-Ssu Huang
Po-Ssu Huang
Identifying highly specific T cell receptors (TCRs) or antibodies against epitopic peptides presented by class I major histocompatibility complex (MHC I) proteins remains a bottleneck in the development of targeted therapeutics. Here, we introduce targeted recognition of antigen–MHC complex reporter for MHC I (TRACeR-I), a generalizable platform for targeting peptides on polymorphic HLA-A*, HLA-B* and HLA-C* allotypes while overcoming the cross-reactivity challenges of TCRs. Our TRACeR–MHC I co-crystal structure reveals a unique antigen recognition mechanism, with TRACeR forming extensive contacts across the entire peptide length to confer single-residue specificity at the accessible positions. We demonstrate rapid screening of TRACeR-I against a panel of disease-relevant HLAs with peptides derived from human viruses (human immunodeficiency virus, Epstein–Barr virus and severe acute respiratory syndrome coronavirus 2), and oncoproteins (Kirsten rat sarcoma virus, paired-like homeobox 2b and New York esophageal squamous cell carcinoma 1). TRACeR-based bispecific T cell engagers and chimeric antigen receptor T cells exhibit on-target killing of tumor cells with high efficacy in the low nanomolar range. Our platform empowers the development of broadly applicable MHC I-targeting molecules for research, diagnostic and therapeutic applications.

6 March 2020 in ACS Chemical Biology
Verified
Journal Article
Closed access
TBTaylor M. Barrett
Taylor M. Barrett
XCXing S. Chen
Xing S. Chen
CLChunxiao Liu
Chunxiao Liu
SGSam Giannakoulias
Sam Giannakoulias
HPHoang Anh T. Phan
Hoang Anh T. Phan
EPE. James Petersson
E. James Petersson

19 July 2021 in Chemical Science
Verified
Journal Article
Open access
PDF file
HPHoang Anh T. Phan
Hoang Anh T. Phan
SGSam Giannakoulias
Sam Giannakoulias
TBTaylor M. Barrett
Taylor M. Barrett
CLChunxiao Liu
Chunxiao Liu
EPE. James Petersson
E. James Petersson
Aberrant levels of cathepsin L (Cts L), a ubiquitously expressed endosomal cysteine protease, have been implicated in many diseases such as cancer and diabetes. Significantly, Cts L has been identified as a potential target for the treatment of COVID-19 due to its recently unveiled critical role in SARS-CoV-2 entry into the host cells. However, there are currently no clinically approved specific inhibitors of Cts L, as it is often challenging to obtain specificity against the many highly homologous cathepsin family cysteine proteases. Peptide-based agents are often promising protease inhibitors as they offer high selectivity and potency, but unfortunately are subject to degradation in vivo. Thioamide substitution, a single-atom O-to-S modification in the peptide backbone, has been shown to improve the proteolytic stability of peptides addressing this issue. Utilizing this approach, we demonstrate herein that good peptidyl substrates can be converted into sub-micromolar inhibitors of Cts L by a single thioamide substitution in the peptide backbone. We have designed and scanned several thioamide stabilized peptide scaffolds, in which one peptide, RS 1A, was stabilized against proteolysis by all five cathepsins (Cts L, Cts V, Cts K, Cts S, and Cts B) while inhibiting Cts L with >25-fold specificity against the other cathepsins. We further showed that this stabilized RS 1A peptide could inhibit Cts L in human liver carcinoma lysates (IC50 = 19 μM). Our study demonstrates that one can rationally design a stabilized, specific peptidyl protease inhibitor by strategic placement of a thioamide and reaffirms the place of this single-atom modification in the toolbox of peptide-based rational drug design.

1 September 2020 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
SGSam Giannakoulias
Sam Giannakoulias
SSSumant R. Shringari
Sumant R. Shringari
CLChunxiao Liu
Chunxiao Liu
HPHoang Anh T. Phan
Hoang Anh T. Phan
TBTaylor M. Barrett
Taylor M. Barrett
EPE. James Petersson
E. James Petersson

12 November 2024 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
JMJason G. Marmorstein
Jason G. Marmorstein
VPVinayak V. Pagar
Vinayak V. Pagar
EHEshe Hummingbird
Eshe Hummingbird
ISIbrahim G. Saleh
Ibrahim G. Saleh
HPHoang Anh T. Phan
Hoang Anh T. Phan
EPE. James Petersson
E. James Petersson

23 October 2024 in Chemical Communications
Verified
Journal Article
Open access
PDF file
HPHoang Anh T. Phan
Hoang Anh T. Phan
YCYanan Chang
Yanan Chang
SESamuel A. Eaton
Samuel A. Eaton
EPE. James Petersson
E. James Petersson
Dipeptidyl peptidase 4 (DPP-4) is a promising biomarker for cancer and metabolic diseases. We demonstrate the design of novel fluorescent DPP-4 probes based on the protease's native substrates using a thioamide as a quencher for measuring in vitro kinetics, inhibition with sitagliptin, and DPP-4 activity in saliva samples.